Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eileen Francis

Eileen Francis is a reporter for “The Tan Sheet,” where she follows news on OTC drug and nutritional product manufacturing, regulation, legislation, finance and research. She previously served as a reporter and editor of “The Rose Sheet,” IBI’s source for in-depth coverage of the cosmetics industry. Early in her career, Eileen worked in public relations and as a writer for a lobbying firm. Outside of IBI, her freelance work includes articles on business, art and travel.
Set Alert for Articles By Eileen Francis

Latest From Eileen Francis

Gottlieb An Anchor For OTC Drug Industry On Stormy Congressional Seas

Commissioner Gottlieb has been a “very strong champion” of FDA and his interest in improving the OTC monograph and switch processes provides hope to the industry during a tumultuous legislative era, say CHPA executives at their annual meeting in Florida. They expect monograph reform will happen this year but doubt much else will happen before mid-term elections in November.

Prescription To Otc Switch Drug Approval Standards

For Successful OTC Switch Proposals, A Good Offense Defends Against Doubters

OTC switch sponsors should identify adversaries early in the application switch process so they can counter arguments that could derail their switch, s consultant advises. Some switches fail because firms target regulatory approval and do little on marketplace performance.

Consumer Prescription To Otc Switch

Perrigo ANDA Approval Brings New Options To Generic Mucinex DM Maximum Strength Portfolio

Perrigo's first OTC drug approved in 2018 is extended-relief guaifenesin 1,200 mg and dextromethorphan 60 mg tablets, planned for launch under its own store brand, Goodsense, as well as distribution for retailer and private label brands. It already distributes the product for store and private label brands through an agreement with Teva.

Consumer Consumer

OTC Switches Face Tougher FDA Evaluations, Less Predictable Process

OTC switch sponsors bear more responsibility than in previous years to convince FDA a product would be safely used and has a strong risk/benefit profile, say Pinney Associates consultants. FDA currently is more conservative on risk/benefit decisions and the advisory committee process isn't productive, they say.

Consumer Consumer

Australia Invests In Medical Cannabis Greenhouse: Health And Wellness Industry News

MYM subsidiary receives AUD$2.5m investment from Australia to build largest medical cannabis greenhouse in the southern hemisphere; dermatology firm Kamedis introduces products for acne, eczema and dandruff; Life Extension rolls out probiotic formulas under its Florassist line; and more health and wellness news in brief.

Consumer Dietary Supplements

Bayer Seeks Stronger Footing In Consumer Health After 2017 Stumble

Bayer consumer health sales fell 9.1% in Q4 and 2.9% for the year as competitive pressure in the US OTC market, especially from lower-price lines and brands sold on e-commerce sites, cut into sales of its Aleve analgesic and Claritin allergy lines. Heiko Schipper takes over as Bayer's consumer business chief and will lead the division in new initiatives to counter competition with increased marketing support for core brands.

Consumer Consumer
See All